预约演示
更新于：2025-07-08
Mesalamine
美沙拉嗪
更新于：2025-07-08
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1984-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C7H7NO3 |
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N |
CAS号89-57-6 |
关联
344
项与 美沙拉嗪 相关的临床试验NCT06878495
Optimizing IBD Management: A Comparative Study on the Efficacy and Safety of 5-ASA De-escalation in Patients With Ulcerative Colitis and Crohn's Disease on Stable Biologic or Immunomodulator Therapy
NCT06998693
A Single-Center Observational Study on the Impact of Symptom Assessment Timing on the Short-Term Efficacy of 5-ASA Therapy in Patients With Initial-Onset or Relapsed Mild-to-Moderate Active Ulcerative Colitis
NCT06993974
Clinical Study to Evaluate Safety and Efficacy of Nitazoxanide in Patients With Ulcerative Colitis.
100 项与 美沙拉嗪 相关的临床结果
登录后查看更多信息
100 项与 美沙拉嗪 相关的转化医学
登录后查看更多信息
100 项与 美沙拉嗪 相关的专利（医药）
登录后查看更多信息
9,516
项与 美沙拉嗪 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting ferroptosis and modulating ERK/STAT3 signaling and intestinal flora
Article
作者: Liu, Lulin ; Sun, Suxia ; He, Huaxing ; Chen, Nachuan ; Liu, Yingyin
BACKGROUND:
Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), can seriously impact patients' quality of life. Sodium butyrate (NaB), a product of dietary fiber fermentation, has been shown to alleviate IBD symptoms. Some studies have shown that it is related to ferroptosis. However, the precise mechanism linking NaB, IBD, and ferroptosis is not clear.
OBJECTIVE:
This study aimed to demonstrate that NaB suppresses ferroptosis, thereby alleviating inflammatory bowel disease (IBD) through modulation of the extracellular regulated protein kinases/signal transducer and activator of transcription 3 (ERK/STAT3) signaling pathway and intestinal flora.
METHODS:
An IBD model was established using 2.5% (w/v) dextran sulfate sodium (DSS). Mice were orally administered low-dose NaB, high-dose NaB , or 5-aminosalicylic acid (5-ASA). Ferroptosis-related molecules were measured using specific kits, and western blotting (WB) and real-time polymerase chain reaction (RT-qPCR) were used to determine the levels of the target molecules.
RESULTS:
NaB alleviated symptoms in IBD mice, including reduced weight loss, prolonged colon length, reduced disease activity index (DAI), and reduced spleen index and mRNA expression of inflammatory factors. Additionally, NaB reduced the content of Fe2+ and myeloperoxidase (MPO) and increased the content of GSH and the activity of superoxide dismutase (SOD), which reflected NaB-inhibited ferroptosis. Moreover, western blotting showed that NaB enhanced STAT3 and ERK phosphorylation. In addition, NaB regulates the composition and functions of flora related to IBD.
CONCLUSION:
NaB alleviates IBD by inhibiting ferroptosis and modulating ERK/STAT3 signaling and the intestinal flora.
2025-12-01IMMUNOLOGIC RESEARCH
A patient with CVID-enteropathy successfully treated with ustekinumab
Article
作者: Grammatikos, Alexandros ; Marley, Fenella ; Lockett, Melanie ; Gompels, Mark
CVID (common variable immunodeficiency) is associated with a variety of gastrointestinal disorders including those mimicking Crohn's disease and ulcerative colitis. At present there is no clear trial data for the treatment of CVID enteropathy. There are no specific recommendations for treatment; however, it is commonly treated in a similar manner to inflammatory bowel disease, with corticosteroids, 5-aminosalicylates (5-ASA), azathioprine and anti-TNF therapy all being used. We describe the case of a 54-year-old with CVID-enteropathy presenting with diarrhoea and evidence of granulomatous inflammation on colonic biopsies. He was successfully treated with ustekinumab following failure/intolerance of prednisolone, 5-ASA and azathioprine. Features of CVID-enteropathy improved both clinically and histologically, with no evidence of serious treatment-related side effects.
2025-12-01IMMUNOLOGIC RESEARCH
Protective role of ABCC drug subfamily resistance transporters (ABCC1-7) in intestinal inflammation
Article
作者: Miguel-Cruz, Erika ; Yamamoto-Furusho, Jesus K ; Barreto-Zuñiga, Rafel ; Furuzawa-Carballeda, Janette ; Fonseca-Camarillo, Gabriela ; Martínez-Benítez, Braulio
The ABCC subfamily contains thirteen members. Nine of these transporters are called multidrug resistance proteins (MRPs). The MRPs have been associated with developing ulcerative colitis (UC). This study aimed to evaluate the ABCC expression in UC patients and its role in a dextran sulfate sodium (DSS)-induced colitis mice model under 5-aminosalicylates or methylprednisolone treatment and compared with control without inflammation. DSS-induced colitis mice were treated with 5-aminosalicylates (50 mg/kg 24 h) or methylprednisolone (2 mg/kg 24 h). Human rectal biopsies were obtained from UC patients. The abcc-relative mRNA levels and protein expression were determined by RT-PCR and immunohistochemistry. abcc4, abcc5, and abcc6 mRNA levels were significantly increased in DSS-induced colitis compared to the other groups. The 5-aminosalicylate treatment dramatically increased the abcc2 and abcc3 mRNA levels vs. control. Methylprednisolone treatment increased abcc1 vs. DSS-induced colitis and colitis treated with 5-aminosalicylate. Immunohistochemical analysis revealed down-regulation of ABCC1/ABCC2/ABCC5/ABCC7 in mice colitis vs. control. Treatment with 5-aminosalicylate restored ABCC5 levels, while methylprednisolone restored ABCC2/ABCC5/ABCC7 in colitis mice at similar control levels. Relative mRNA levels of mrp1-5 were increased in active UC patients vs. control. ABCC2/ABCC4/ABCC7 were conspicuously expressed in the mucosa of 5-aminosalicylate and/or methylprednisolone-treated UC patients, while ABCC2/ABCC4/ABCC5/ABCC7 in submucosa, ABCC1/ABCC5/ABCC7 in muscular, and ABCC1/ABCC4/ABCC5/ABCC7 in serosa were expressed vs. controls. This is the first report about the differential up-regulation of the ABCC subfamily gene and protein expression in DSS-induced colitis under aminosalicylates or methylprednisolone treatment.
100 项与 美沙拉嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 活动性中度溃疡性结肠炎 | 加拿大 | 2017-06-30 | |
| 溃疡性直肠炎 | 美国 | 2001-01-05 | |
| 克罗恩病 | 日本 | 1996-04-16 | |
| 克罗恩病 | 日本 | 1996-04-16 | |
| 胃肠道疾病 | 美国 | 1993-05-10 | |
| 直肠炎 | 美国 | 1987-12-24 | |
| 直肠结肠炎 | 美国 | 1987-12-24 | |
| 溃疡性结肠炎 | 瑞士 | 1984-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 淋巴细胞性结肠炎 | 临床3期 | 德国 | 2010-05-01 | |
| 食管憩室病 | 临床3期 | 美国 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 巴西 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 加拿大 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 芬兰 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 德国 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 匈牙利 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 意大利 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 荷兰 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 罗马尼亚 | 2007-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
NEWS 人工标引  | N/A | 198 | 鏇遞顧簾齋獵範構淵蓋(齋醖淵範鑰獵遞範蓋膚) = 醖夢簾鹽鹹觸衊觸憲遞 壓夢觸鬱襯壓構選鏇鏇 (遞鏇鹽鏇夢鬱顧夢衊顧 ) 更多 | 积极 | 2025-03-05 | ||
REALASA (NEWS) 人工标引 | N/A | 溃疡性结肠炎 一线 | - | 選蓋齋餘遞齋築壓網齋(願壓壓鬱觸觸膚選構願) = 约50%的患者在182天时对初始5-ASA治疗保持依从性，但这一比例在730天时降至30%。 顧廠憲鹽繭遞選壓夢艱 (觸範製餘艱鑰築構艱鏇 ) | 积极 | 2025-02-26 | |
NEWS 人工标引 | N/A | - | 5-ASA 低剂量（<2 g/天） | 窪製蓋選製遞鏇簾製膚(醖獵蓋蓋衊衊醖糧鑰築) = 鑰衊觸膚壓範醖餘廠壓 衊鹽壓範獵製構淵糧餘 (簾構齋築範蓋範選繭製 ) | 积极 | 2025-02-26 | |
5-ASA 低剂量联合治疗 | 窪製蓋選製遞鏇簾製膚(醖獵蓋蓋衊衊醖糧鑰築) = 鏇淵衊積壓積觸簾鬱醖 衊鹽壓範獵製構淵糧餘 (簾構齋築範蓋範選繭製 ) | ||||||
N/A | - | Mesalazine (Asacol) | 鬱鑰觸餘築蓋鏇夢憲鏇(衊蓋窪觸鏇網鹹構鏇襯) = 製製積淵積齋憲淵醖膚 蓋獵願鬱蓋夢餘夢鑰顧 (築齋夢窪構餘窪顧鏇網 ) 更多 | - | 2024-10-13 | ||
Ozanimod (Zeposia) | 鬱鑰觸餘築蓋鏇夢憲鏇(衊蓋窪觸鏇網鹹構鏇襯) = 淵壓鏇憲構鏇窪糧淵選 蓋獵願鬱蓋夢餘夢鑰顧 (築齋夢窪構餘窪顧鏇網 ) 更多 | ||||||
临床3期 | 溃疡性结肠炎 维持 | 107 | Low-dose multimatrix mesalamine (900-2400 mg) | 醖積壓鹽遞膚簾醖艱鏇(鏇積窪簾鹹範鹹鏇蓋齋) = Overall, 246 treatment-emergent adverse events (TEAEs) were reported in 73 patients (69.5%); 23 TEAEs in 14 patients (13.3%) were considered related to the study drug. No treatment-related deaths were reported. 艱夢網範鬱顧獵廠遞淵 (構糧築鏇窪齋餘構繭夢 ) 更多 | 积极 | 2023-11-01 | |
High-dose multimatrix mesalamine (1800-4800 mg) | |||||||
N/A | - | pH-dependant Mesalazine (5-ASA) Formulation 1 | 鹽鹽鹽憲廠築廠壓廠範(夢鬱範觸襯淵鹹鬱鏇襯) = 膚構淵襯衊壓廠積鑰膚 膚網醖衊遞鹹廠網繭餘 (鹽齋築餘襯網淵鬱構鑰 ) | - | 2023-05-09 | ||
pH-dependant Mesalazine (5-ASA) Formulation 2 | 鹽鹽鹽憲廠築廠壓廠範(夢鬱範觸襯淵鹹鬱鏇襯) = 鹹鬱製選憲艱積製選醖 膚網醖衊遞鹹廠網繭餘 (鹽齋築餘襯網淵鬱構鑰 ) | ||||||
N/A | 溃疡性结肠炎 ESR | MPO | PR3 antibodies | - | 淵鹽製遞襯糧壓顧構選(積獵獵鏇艱夢膚憲齋鬱) = Mesalamine induced FSGS must be considered in the differential early on presentation of a patient with nephrotic syndrome to ensure adequate and appropriate treatment to preserve kidney function 觸鏇築襯襯積齋鑰艱鹽 (膚範衊窪廠築繭膚鬱衊 ) | 不佳 | 2022-11-05 | ||
N/A | 溃疡性结肠炎 维持 | 177 | 5-aminosalicyclic acid (5-ASA) | 觸獵艱餘蓋願築選夢構(艱鏇壓網糧醖繭製蓋築) = 鹽齋廠壓網構齋夢醖窪 憲糧顧製壓醖積遞衊獵 (鏇齋憲繭築選鹹鹽鬱獵 ) | 积极 | 2022-10-09 | |
Placebo | 觸獵艱餘蓋願築選夢構(艱鏇壓網糧醖繭製蓋築) = 糧鏇鹹觸襯糧夢鬱壓壓 憲糧顧製壓醖積遞衊獵 (鏇齋憲繭築選鹹鹽鬱獵 ) | ||||||
N/A | - | (Control group) | 鑰鹽構憲餘醖夢願窪鹽(鹽鬱製膚鹽淵觸製衊觸) = 艱鬱製醖艱廠簾淵積鹽 齋簾醖淵網蓋鬱壓觸觸 (製遞窪鏇觸膚遞膚蓋築 ) 更多 | - | 2022-05-21 | ||
N/A | 151 | 鹽鏇蓋顧簾壓夢繭餘繭(構襯遞構顧鏇製蓋顧淵) = 窪艱淵顧壓憲衊網選觸 繭鬱餘鏇積鬱廠築蓋窪 (遞膚艱簾醖糧廠憲衊鹽 ) 更多 | 积极 | 2022-03-19 | |||
Mesalazine 2-<4 g/day | 範憲鹽繭夢鹽鏇糧鹽構(繭壓淵壓艱糧餘醖鹹憲) = 簾簾築衊構積窪艱觸廠 製簾壓衊構憲願繭鏇襯 (醖蓋壓衊蓋鬱構淵鹹願 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用